Sim­ba Gill stay­ing on at Evelo to weath­er lay­offs and a PhII fail

Sim­ba Gill will be stay­ing put as CEO of Evelo Bio­sciences for now.

Gill an­nounced last year that he would be leav­ing the head po­si­tion at Evelo to take on the role of ex­ec­u­tive part­ner at Flag­ship Pi­o­neer­ing. He was aim­ing to stay on un­til a suc­ces­sor was se­lect­ed, but there’s a new course of ac­tion in the wake of a Phase II miss and a re­duced head­count.

“I want to em­pha­size that I re­main per­son­al­ly com­mit­ted to Evelo and stay­ing on to lead the or­ga­ni­za­tion. I con­tin­ue to be­lieve that Evelo is a re­mark­able op­por­tu­ni­ty in terms of the sci­ence, the plat­form, the type of prod­ucts that we’re able to pro­duce, and most im­por­tant­ly, the po­ten­tial of mil­lions of pa­tients suf­fer­ing from all stages of in­flam­ma­to­ry dis­ease,” Gill said on a con­fer­ence call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER